Abstract:The National Occupational Research Agenda (NORA) was first established in 1996 by the National Institute for Occupational Safety and Health (NIOSH) and its partners as a framework to guide occupational safety and health research for the decade that followed. The process to develop NORA resulted in 21 research priorities, which can be found in the original document. NORA arose from the recognition that occupational safety and health research in both the public and the private sectors would benefit from targeting limited resources at important priorities. The creators of NORA also recognized the need to address changes in the workplace, as well as the increasingly diversified work force, in the United States. The distribution of jobs in the United States economy continues to shift from manufacturing to services. Longer hours, compressed work weeks, shift work, reduced job security, and part-time and temporary work are realities of the modern workplace. NORA continues to address the broadly recognized need to focus research in the areas with the highest likelihood of reducing the still significant toll of workplace injury and illness. Each day, an average of 9,000 workers in the United States sustain disabling injuries on the job, 16 die of injuries sustained at work, and 137 die of work-related diseases. The economic burden of this continuing toll is high. Data from a NIOSH-funded study reveal direct and indirect costs of occupational injuries and illnesses to be $171 billion annually ($145 billion for injuries and $26 billion for illnesses), compared with $33 billion for acquired immunodeficiency syndrome, $67.3 billion for Alzheimer’s disease, $164.3 billion for circulatory diseases, and $170.7 billion for cancer. Building on the success of NORA, development of the second decade of NORA began in 2005 and will use a sector-based approach. NIOSH and its partners will form eight Sector Research Councils (Figure), including participants from academia, industry, labor, and government. Each council will draft sector-based research goals, objectives, and action plans to provide guidance to the entire occupational safety and health community for moving research to practice in workplaces. In addition, a Cross-Sector Research Council will be formed to identify opportunities for common research across the sectors. Several town hall meetings are being conducted around the United States to help guide development of the second decade of NORA by gaining input from occupational safety and health stakeholders and partners, labor and employer groups, professional societies, academics, employers, workers, state and local public health officials, and elected officials. The goals of these meetings are to:

Insulin-like Growth Factor Binding Protein-Related Protein 1 Mediates VEGF-induced Proliferation, Migration and Tube Formation of Retinal Endothelial Cells.

VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway

Association of Placental Growth Factor and Angiopoietin in Human Retinal Endothelial Cell-Pericyte co-Cultures and iPSC-Derived Vascular Organoids

Targeting of Integrin-Linked Kinase with Small Interfering RNA Inhibits VEGF-Induced Angiogenesis in Retinal Endothelial Cells

Ginsenoside Rg1 Inhibits High Glucose-Induced Proliferation, Migration, and Angiogenesis in Retinal Endothelial Cells by Regulating the lncRNA SNHG7/miR-2116-5p/SIRT3 Axis

Targeting long non-coding RNA RP11-502I4.3 delays the trend of angiogenesis in diabetic retinopathy

Direct Repression of IGF2 is Implicated in the Anti-Angiogenic Function of Microrna-210 in Human Retinal Endothelial Cells

PGF2α Facilitates Pathological Retinal Angiogenesis by Modulating Endothelial FOS‐driven ELR + CXC Chemokine Expression

Some extrageniculate visual pathways in the cat.

Placental Growth Factor Expression is Reversed by Antivascular Endothelial Growth Factor Therapy under Hypoxic Conditions

Insulin-like growth factor binding protein-related protein 1 and cancer.

Angiogenic Factor with G Patch and FHA Domains 1 Protects Retinal Vascular Endothelial Cells under Hyperoxia by Inhibiting Autophagy

AIP1 Regulates Ocular Angiogenesis Via NLRP12‐ASC‐Caspase‐8 Inflammasome‐Mediated Endothelial Pyroptosis

Autophagy is required for the promoting effect of angiogenic factor with G patch domain and forkhead-associated domain 1 (AGGF1) in retinal angiogenesis

The National Occupational Research Agenda—The Second Decade of NORA

VEGF-B prevents chronic hyperglycemia-induced retinal vascular leakage by regulating the CDC42-ZO1/VE-cadherin pathway

Quercetin Inhibits Vascular Endothelial Growth Factor-Induced Choroidal and Retinal Angiogenesis in Vitro

RTEF-1 Attenuates Blood Glucose Levels by Regulating Insulin-Like Growth Factor Binding Protein-1 in the Endothelium

Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis

Deletion of endothelial IGFBP5 protects against ischaemic hindlimb injury by promoting angiogenesis